Jonathan R. LaRochelle

Relay Therapeutics (United States) US

0000-0002-3301-7904

Publications

1,808

Citations

H-Index

i10-Index

0.08

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Peripheral RIPK2 degradation improves neurological outcomes after experimental ischemic stroke.

J. Howell, Jonathan Larochelle, Mia Strawser, Solange De La Vega Mulet, Ryland J. Tishko - Journal of Cerebral Blood Flow and Metabolism, 2026

Cited by 0 Semantic Scholar

Flow diversion for the treatment of IA in France : preliminary results of the impact fr registry

Jonathan Larochelle, J. Gentric, E. Kalsoum, A. Quentin, X. Barreau - Journal of neuroradiology, 2025

Cited by 0 Semantic Scholar

Improved Rapid Equilibrium Dialysis-Mass Spectrometry (RED-MS) Method for Measuring Small Molecule-Protein Complex Binding Affinities in Solution.

B. Choi, C. Han, Jonathan Larochelle, W. Pitsawong, Damian Houde - Journal of the American Society for Mass Spectrometry, 2024

Cited by 3 Semantic Scholar

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia OA

A. Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce - Cancer Discovery, 2023

Cited by 52 Semantic Scholar

Abstract P5-16-10: RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models

Ermira Pazolli, Randy Kipp, A. Boezio, H. Gunaydin, Amanda Iskandar - Cancer Research, 2022

Cited by 1 Semantic Scholar

Research Topics

PI3K/AKT/mTOR signaling in cancer (50) Lung Cancer Treatments and Mutations (32) Metabolism and Genetic Disorders (15) Advanced Breast Cancer Therapies (15) Protein Tyrosine Phosphatases (10)

Affiliations

Université du Québec à Chicoutimi

CA 1991 - 1991

Harvard University

US 2021 - 2016

Yale University

US 2019 - 2012

Boston VA Research Institute

US 2021 - 2019

Relay Therapeutics (United States)

US 2024 - 2022

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers

Jonathan R. LaRochelle

Publication & Citation Trends

Publications

Peripheral RIPK2 degradation improves neurological outcomes after experimental ischemic stroke.

Flow diversion for the treatment of IA in France : preliminary results of the impact fr registry

Improved Rapid Equilibrium Dialysis-Mass Spectrometry (RED-MS) Method for Measuring Small Molecule-Protein Complex Binding Affinities in Solution.

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia OA

Abstract P5-16-10: RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models

Research Topics

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back